News

HemoShear Therapeutics Appoints Patrick Horn, MD, PhD, Chief Medical Officer

Industry Veteran Will Lead HST5040 and Future Rare Disease Clinical Programs

HemoShear Therapeutics, Inc., a privately held biotechnology company developing drugs for rare metabolic disorders, has appointed Patrick Horn, MD, PhD, as Chief Medical Officer, effective January 1, 2022. Dr. Horn will lead the company’s growing clinical operations, clinical development, regulatory affairs, medical affairs, biometrics and pharmacovigilance functions. After practicing pediatrics for nearly 20 years, Dr. Horn has spent more than two decades leading successful clinical programs for large and small biotech companies.

 

“Pat has extensive medical knowledge and clinical development experience to lead our drug HST5040 through clinical studies and regulatory activities for methylmalonic acidemia and propionic acidemia, two rare metabolic diseases with no effective treatment options,” said Jim Powers, chairman and CEO of HemoShear Therapeutics. “Pat’s experience building highly effective teams and shepherding rare disease drugs to market will be invaluable as we advance our pipeline of inherited rare disease therapies.”

Dr. Horn’s experience spans all phases of rare pediatric drug development, from Phase 1 through regulatory approval and product launch. Most recently, he served as Chief Medical Officer for Albireo Pharma, where he led the team that achieved accelerated marketing approvals in the US and Europe for BylvayTM in progressive familial intrahepatic cholestasis (PFIC).  He also designed and initiated pivotal clinical development programs in biliary atresia and Alagille syndrome.  Prior to Albireo, he led clinical development programs in hereditary angioedema, homocystinuria, and infectious disease. Dr. Horn has formal training and extensive experience in clinical pharmacology.  He received his MD and PhD from the University of Chicago and completed a pediatric residency at Boston Children’s Hospital. Prior to transitioning to industry, Dr. Horn was a practicing pediatrician at major academic institutions in Chicago.

“I am excited to join HemoShear’s dedicated team as we continue our current clinical trial and plan additional global studies of HST5040 to treat methylmalonic acidemia and propionic acidemia as well as make progress in our early stage pipeline,” said Dr. Horn. “I look forward to collaborating with our team and the metabolic disease community to raise awareness of clinical trial opportunities, encourage early diagnosis and make progress to improve health outcomes for patients born with these devastating disorders.”

Read more here.

Recent News

09/22/2023

State public health laboratory, Henrico County Schools launch pilot program to promote life science career

More than 50 Henrico County high school students and teachers joined scientists from Virginia’s public health and environmental laboratory Wednesday to kick off an innovative program that brings together private and government scientists and experts, business and nonprofit leaders, and public schools to explore ways to create a pipeline of talent to fuel Virginia’s growing

09/21/2023

Climate Tech Startup ThermaGEL Innovations’ Breakthrough Aerogels Join the Challenge to Save Half-Gigaton of C02 Emissions Each Year

In the fight against climate change, properly insulating homes and buildings can significantly raise energy efficiency and indoor air quality while lowering carbon dioxide emissions. A startup company, spun out of research at Virginia Commonwealth University, is commercializing what it calls a breakthrough in low-cost insulation materials. ThermaGEL Innovations has developed insulation material using aerogels,

09/20/2023

Charlottesville healthy sugar innovator Bonumose raises $2M

Bonumose Inc., a Charlottesville startup specializing in table sugar alternatives, has raised $2 million toward a $10 million funding round after German flavor and fragrances producer Symrise AG signed a minority investment agreement with the company. “The strategic investment from Symrise is part of a larger funding round that will be used for increasing sales,